A mouse model of unresectable hepatocellular carcinoma (HCC) post-transplant exercise could enhance the effect of combination therapy with anti-PD-1 and the tyrosine kinase inhibitor Lenvatinib. The gene discussed is PDCD1; the disease is hepatocellular carcinoma.